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 Pruritus is one of the main factors in the progression of canine allergic 
dermatitis. Pruritus-inducing behaviors, such as scratching and rubbing, 
impair the skin barrier. Consequently, the damaged skin barrier aggravates 
the severity of allergic dermatitis by enhancing penetration of allergens. 
Oclacitinib is a janus kinase 1 (JAK-1) inhibitor that blocks the signals of 
IL-31, a pruritogenic cytokine. Because of the mechanism, oclacitinib has 
been used to reduce pruritus in dogs with allergic dermatitis. The purpose 
of the study was to evaluate the effect of oclacitinib on skin barrier 
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function in dogs with allergic dermatitis by measuring transepidermal water 
loss (TEWL), while assessing its efficacy and safety. Oclacitinib was 
administered for 84 days; twice a day for the first 2 weeks and then once a 
day for the remaining period (day 0-28: n=22, day 29-84: n=8). In addition 
to TEWL, the canine atopic dermatitis extent and severity index-4 
(CADESI-4), pruritus visual analog scale (PVAS) and owner satisfaction  
were measured to evaluate the efficacy of oclacitinib on days 0, 14, 28, 56, 
and 84. Any abnormal health conditions during the experimental period were 
recorded and blood samples were collected on days 0, 28, and 84 to 
evaluate the safety of the medication. The administration of oclacitinib 
decreased both CADESI-4 and PVAS values significantly from baseline at 
all assessment points, regardless of the daily dosage (p<0.05). Unlike 
CADESI-4 and PVAS, TEWL values decreased significantly from baseline 
only on day 14 for the total TEWL value, including ventral neck and 
axilla-specific TEWL values (p<0.05). In conclusion, oclacitinib was found 
to exert a remarkable effect on skin barrier function when the drug was 
administered twice daily. Although the skin barrier function seemed to be 
aggravated with the reduction in daily dosage, the changes did not markedly 
affect visible skin condition or the severity of pruritus. Most owners were 
content with the oclacitinib treatment for their dogs and the medication was 
used safely in most patients without causing any significant adverse events. 
Therefore, this study showed that oclacitinib was effective and safe treatment 
for the control of canine allergic dermatitis.
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Pruritus plays a major role in the progression of canine allergic dermatitis 
[7]. The unpleasant sensation due to allergic dermatitis could make dogs 
scratch, rub, or lick their bodies, and these behaviors cause skin damage 
[22]. Through the impaired skin barrier, the penetration of allergens is 
facilitated [5] and cause inflammatory process that potentially induces 
pruritus resulting in scratching, which is called “pruritus-scratch” cycle [22]. 
In this cycle, nervous system is known to be a crucial component of 
pruritus [22]. Pruritus mediators that are released upon inflammation 
stimulate the receptors on pruritus-specific sensory neurons, which convey 
signals to the region of the brain associated with pruritus sensation [22]. In 
the neuronal pathway, interleukin (IL)-31 plays a key role as a pruritogenic 
cytokine by activating janus kinase (JAK) 1 enzyme which is involved in 
signal transduction of various pruritogenic, pro-inflammatory, and pro-allergic 
cytokines [1, 6, 8, 19, 21]. This concept has led many researchers to have 
increased interest in the interaction between IL-31 and JAK 1 to control the 
vicious cycle of canine allergic dermatitis.    
  
Oclacitinib (Apoquel® , Zoetis ; FlorhamPark, NJ, USA) is a predominant 
JAK-1 inhibitor that blocks the signals of IL-31 [3, 8]. With the feature of 
oclacitinib, it targets pruritus-associated neuronal pathways and it has been 
suggested as a new alternative medication for dogs with allergic dermatitis 
[3, 7, 11]. The efficacy of oclacitinib has been proved in many studies 
through evaluation of canine atopic dermatitis extent and severity index 
(CADESI) and pruritus visual analog scale (PVAS) [3, 4]. CADESI is an 
- 2 -
index for grading skin lesions [18] and PVAS is a scale used for the 
assessment of pruritus intensity [9]. 
 In addition to these two methods, transepidermal water loss (TEWL) 
which is defined as the amount of water passing from inside a body to the 
outside through the epidermis has been used as a research tool to evaluate 
skin barrier function not only in human but also in canine dermatology [2, 
5, 10, 24]. Dogs with allergic dermatitis are known to have impaired skin 
barrier function and higher TEWL values than dogs with healthy skin [2, 
17]. Since impaired skin barrier function is considered a crucial factor for 
allergic sensitization by increasing allergen penetration [13], TEWL 
assessment has been used to evaluate the effect of skin treatments in dogs 
with allergic dermatitis such as atopic dermatitis [10, 24]. However, the 
effect of oclacitinib on TEWL in canine allergic dermatitis has not been 
assessed so far. Therefore, this study was to evaluate the effect of 
oclacitinib on skin barrier function via TEWL assessment and to investigate 




The present study was a non-blinded, single-arm trial. Basically, all dogs 
that participated in the study were required to receive oclacitinib  (Apoquel®, 
Zoetis; FlorhamPark, NJ, USA) for at least 28 days ± 2 days and some of 
them whose owners approved the extended treatment continued to receive 
oclacitinib up to day 84 ± 2 days. Assessments were carried out on days 0, 
14, 28, 56, and 84.
2. Animals and management
All animals were client-owned dogs diagnosed as allergic dermatitis. The 
diagnosis of allergic dermatitis was based on medical history, typical clinical 
signs, positive results of serum allergen-specific IgE test, food elimination 
trials to confirm food allergy, and/or intradermal skin test. The dogs were 
fed on commercial hypoallergenic diets during oclacitinib treatment. The 
exclusion criteria included dogs with ectoparasitosis and severe infection; 
dogs with immunosuppressive conditions such as demodicosis, 
hyperadrenocorticism, hypothyroidism, or progressive malignant tumor; dogs 
that did not receive proper medication; dogs withdrawn from the study by 
their owners for any reason; and pregnant dogs and lactating bitches. They 
were not allowed to receive any immunosuppressive drugs such as 
glucocorticoids or cyclosporine but allowed to take antibiotics if needed. The 
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purpose of the study was fully explained to the owners and written 
informed consent was obtained from all owners.
3. Drug administration 
Dogs were administered with oclacitinib at a dose of 0.4-0.6 mg/kg orally 
twice a day for 14 days and then once a day as maintenance therapy. Day 
1 was defined as the first day of dosing. 
4. Evaluation Procedure
 4.1  Lesion severity 
 CADESI-4 is a four-point scale used to score lesion severity. It was 
designed to score skin lesions such as erythema, lichenification, alopecia, 
and excoriation as follows: none (score 0), mild (score 1), moderate (score 
2), and severe (score 3) [18]. The maximal score of CADESI-4 is 180 and 
the proposed limits of mild, moderate, and severe skin lesions are 10, 35, 
and 60, respectively [18]. CADESI-4 was evaluated only for dogs that 
received oclacitinib as scheduled and it was measured by a designated 




The PVAS scale consists of six levels of pruritus, represented on a 10-cm 
line, categorized as follows [3]: normal dog with no itching (0 cm); very 
mild and occasional episodes of itching (2 cm); more frequent episodes of 
mild itching when the dog is awake with occasional episodes of itching at 
night (4 cm); regular episodes of moderate itching when the dog is awake 
(6 cm); prolonged episodes of severe itching when the dog is awake and 
even when the dog is eating, playing, exercising, or distracted (8 cm); 
extremely severe itching with continuous scratching, chewing and/or licking, 
regardless of the surrounding circumstances or activities of the dog (10 cm). 
PVAS was evaluated only for dogs that received oclacitinib as scheduled 
and it was measured by the respective owners. 
 4.3 Skin barrier function 
　TEWL was evaluated with evaporimeter (vapometer® SWL-3, Delfin 
Technologies Ltd., Kuopio, Finland), a closed chamber that is unaffected by 
ambient air flows, thereby reducing the variability in values [2]. The 
procedure was carried out in a designated room to minimize possible 
variations in ambient temperature and humidity. The ambient temperature 
(20-23℃) and relative humidity (20-40%) of the room were within the 
manufacturer’s recommended range. On the day of assessment, dogs were 
not allowed to be washed [20]. TEWL measurement was carried out three 
times for each site on each designated day and then the median values were 
used for analysis. The normal TEWL range has not been established in dogs 
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yet but in humans. The mean TEWL values were reported to be 8.2 ± 4.9 
g/h/m2 for forearm anterior, 18.3 ± 9.4 g/h/m2 for forehead, and 13.1 ± 7.1 
g/h/m2 for cheek in healthy women [14]. The regions for the TEWL 
measurement were chosen based on the density of hair as follows: left side 
of medial pinna, ventral neck, axilla, and inguinal regions, since the TEWL 
values measured on the sparsely haired regions such as ear and inguinal 
regions are known to show no significant changes over 48 hours [16]. In 
this study, total TEWL values with the sum of TEWL for all four regions 
and region-specific TEWL values were analyzed respectively. TEWL were 
evaluated only for dogs that received oclacitinib as scheduled and it was 
measuerd by a designated veterinarian to minimize data variation.
 4.4 Owner satisfaction
　The owners were asked if they were satisfied with the oclacitinib treatment 
for their dogs on each assessment day. The extent of owner satisfaction was 
expressed on a scale of 1–100 points and the results were categorized as 
follows: 100-75, strongly satisfied; 74-50, satisfied; 49-25, neutral; and 24-1, 
dissatisfied. 
4.5 Safety 
 All dogs received at least one dose of oclacitinib and were included in 
safety assessment. Any abnormal health conditions during the study were 
recorded by asking owners on every designated assessment day and they 
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were required to report any adverse events occurred to their dogs on 
oclacitinib treatment by making a call when they were away from a 
hospital. Hematologic and serum chemical parameters were evaluated on 
days 0, 28, and 84.
5. Statistical analyses
 Efficacy assessments were analyzed with IBM SPSS statistics software, 
version 23 (SPSS Inc., Chicago, IL, USA). Normality of values was 
assessed by Shapiro-Wilk test. To compare the difference in results between 
baseline and each assessment point for different dosages, a paired t-test or 
Wilcoxon signed rank test was used based on the normality of values. 




In total, 24 dogs were enrolled in the study. Shih-tzu (20.8%) and Poodle 
(16.6%) were the most common breeds and the rest was comprised of 
Maltese, Dachshund, Labrador Retriever, French Bulldog, Beagle, Lakeland 
Terrier, Bull Terrier, Bichon Frise, and Pekingese. All dogs were pure 
breeds with 33.3% female and 66.6% male dogs of which 12.5% of the 
dogs were sexually intact. The mean age was 6.9 (1-14) years and the mean 
weight was 9.1 (3.2-32) kg (Table 1). Prior to the administration of 
oclacitinib, the mean values of CADESI and PVAS were 56.5 ± 19.7 and 
6.9 ± 1.6, respectively. The TEWL median values on day 0 were as 
follows: 24.3 (13.8-47.9) g/h/m2 on Lt. medial pinna, 40.0 (25.2-116.8) 
g/h/m2 on Lt. ventral neck, 29.0 (16.0-88.4) g/h/m2 on Lt. axilla, and 12.7 




　Among the 24 dogs enrolled, two dogs were withdrawn due to the 
occurrence of demodicosis during the study. Therefore, a total of, 22 dogs 
were administered with oclacitinib at least for 28 days (± 2 days). Among 




 3.1 Lesion severity 
 The mean CADESI-4 values declined significantly from 56.5 ± 19.7 to 
35.0 ± 20.1, 31.7 ± 21.8, 23.4 ± 12.5, and 25.3 ± 11.0 on days 14, 28, 
56, and 84, respectively (p<0.05; Figure 1).
 3.2 Pruritus 
 
The mean PVAS values declined significantly from 6.9 ± 1.6 to 2.4 ± 1.5, 
4.3 ± 1.8, 3.2 ± 2.3, and 2.4 ± 1.6 on days 14, 28, 56, and 84, 
respectively (p < 0.05; Figure 2). Although the values tend to rebound on 
day 28, values on day 56 and 84 showed a decreasing trend. 
 3.3 Skin barrier function 
 
With regard to region-specific TEWL values, the results varied depending 
on the measured regions. Significant differences were observed only on day 
14 for the left side of ventral neck and axilla (p<0.05; Figure 3A). The 
median TEWL values of ventral neck reduced from 40.0 (14.8-76.8) to 23.3 
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(7.8-11.4) g/h/m2, and the values of axilla reduced from 29.0 (13.0-59.5) to 
17.2 (5.6-9) g/h/m2 on day 14. In case of the left side of medial pinna and 
inguinal region, no significant differences were observed during the study 
(Figure 3A). In case of total TEWL, all the median values following 
treatment were lower than the value of baseline. However, the significant 
difference was founded only on day 14 by decreasing from 107.1　 (71.2- 
311.6) g/h/m2 to 68.7 (53.0-109.3) g/h/m2 (p<0.05; Figure 3B). 
3.4 Owner satisfaction
 The percentage of owners with a score more than 75 out of 100 points (a 
rating of highly satisfied), was 76.2, 52.4, 87.5, and 87.5% on days 14, 28, 
56, and 84, respectively. The percentage of owners with a score between 50 
and 74 (a rating of satisfied), was 28.6, 47.6, 0, and 12.5% on days 14, 28, 
56, and 84 respectively. The percentage of owners with a score between 25 
and 49 (a rating of neutral), was 0, 4.8, 12.5, and 0% on days 14, 28, 56, 
and 84, respectively. No scores of less than 25 (a rating of dissatisfied) 
were recorded for the oclacitinib treatment (Figure 4). 
4. Safety evaluation
 4.1 Abnormal clinical signs
 Among the 24 dogs enrolled, 2 were withdrawn from the study due to 
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the occurrence of demodicosis within the first 4 weeks of therapy. The 
abnormal clinical signs were as follows: vomiting (16.6%, 4 dogs), lethargy 
(12.5%, 3 dogs), polydipsia (8.3%, 2 dogs), aggression, anorexia, and 
diarrhea (4.1%, 1 dog each). Most clinical signs were mild, transient, and 
resolved spontaneously with continued dosing. Cystitis and pancreatitis were 
also found (4.3%, 1 dog each) and the administration of oclacitinib was 
temporally skipped while resolving the adverse events. 
 4.2 Hematology and serum chemistry
  Most of the changes in hematological and serum chemistry values were 
minor, remained within laboratory reference ranges, nor accompanied with 
any clinical signs. There were a few remarkable changes such as a decrease 
in neutrophil or platelet count (12.5%, 3 dogs each) and an increase in total 
cholesterol (16.6%, 4 dogs), alanine aminotransferase (ALT) (8.3%, 2 dogs), 
and alkaline phosphatase (ALP) (4.1%, 1 dog).
 4.3 Concomitant medications
 
  Various antibiotics such as amoxicillin, cefovecin, cephalexin and 
ciprofloxacin were administered during the study. Among the 22 dogs which 
finished the study as scheduled, 7 (31.8%) received antibiotics temporally 
due to the mild infection that occurred before oclacitinib treatment, but these 
animals did not show any adverse events during the administration of 
antibiotics. 
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                         DISCUSSION
The present study proved that oclacitinib improved visible skin lesions and 
the severity of pruritus associated with canine allergic dermatitis as 
confirmed through assessment of CADESI-4 and PVAS values, which were 
similar to the results of previous studies [3, 4, 12]. Even though PVAS 
values showed a fluctuating pattern, both CADESI-4 and PVAS values after 
treatment significantly reduced from their baseline regardless of the daily 
dosages administered during the study. It is believed that the observed 
pattern in PVAS values was related to the daily dosage reduction, since 
many owners reported that their dogs seemed to scratch more often when 
the daily dosage was reduced to half by reducing its frequency from twice 
to once daily. 
Regarding the effect of oclacitinib on skin barrier function, total TEWL 
values were more influenced by the daily dosage of oclacitinib than the 
other two parameters were, especially CADESI-4. In the present study, 
significant changes in total TEWL values including ventral neck and 
axilla-specific values from baseline were reported only on day 14 when 
oclacitinib was administered twice daily. However, no significant differences 
were observed after the dosage was reduced to half i.e., from twice daily to 
once daily. The changes in TEWL values might be related to the increased 
severity of pruritus due to the reduction of daily dosage after the first 2 
weeks of treatment. The daily dosage reduction might trigger and increase 
pruritus-related behaviors such as scratching or rubbing, as shown in the 
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results of PVAS, and these behaviors might damage the skin barrier 
resulting in the increase in TEWL values. However, the extent of skin 
barrier damage did not seem severe enough to aggravate visible skin lesions, 
since all the CADESI-4 values following treatment significantly reduced 
from baseline regardless of the daily dosages. This can be explained by the 
fact that the TEWL evaluation detects disturbances in the protective function 
of skin barrier at an early stage, even before they are visible [15]. In the 
present study, both total TEWL and region-specific TEWL were analyzed. 
For a better understanding of the effect of oclacitinib on skin barrier 
function, the assessment of total TEWL seemed to be more reliable than the 
assessment of a region specific TEWL since all dogs had lesions at different 
regions and if an investigator selects only one or a few regions for TEWL 
assessment, the result could be biased. In a previous study analyzing the 
influence of cyclosporine on TEWL, the mean TEWL value was calculated 
from 10 different regions and showed a significant decline with cyclosporine 
treatment; 6 out of 10 regions contributed to the statistical significance [24]. 
Similarly, the present study, two of the four regions contributed to the 
statistical significance of total TEWL. 
During the study, most owners found the oclacitinib treatment acceptable 
for their dog. In particular, the majority of owners showed strong 
satisfaction throughout the study period. Although the percentage of owners 
who were 'strongly satisfied' decreased sharply on day 28, when the 
frequency of the daily dosage was reduced to half, this percentage 
dramatically rebounded on day 56 and accounted for a high portion of 
owners until the end of the study, similar to the results for PVAS. From 
the evaluation of the owners, it was inferred that the abrupt reduction of 
daily dose could negatively influence the owner's compliance for the therapy. 
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With respect to the recovery pattern in PVAS and the owner satisfaction 
scores from day 56 onwards, it would be important to explain the 
fluctuations of the effect of oclacitinib to owners before starting therapy, in 
order to enhance compliance. 
Regarding safety, treatment with oclacitinib did not cause any significant 
adverse events and most of them were mild and transient. There were a few 
dogs that required cessation and temporary discontinuation of oclacitinib 
treatment due to the development of adverse events such as demodicosis, 
cystitis, and pancreatitis. First, one dog diagnosed with demodicosis was 
incorrectly administered oclacitinib with the wrong regimen (twice daily for 
3 weeks) by the owner. Second, the dog that developed cystitis was found 
to have a medical history of cystitis before the oclacitinib treatment. Finally, 
in the case of the dog diagnosed as pancreatitis, oclacitinib administration 
was repeated after the resolution of pancreatitis and the adverse event did 
not reoccur. Therefore, it was unclear if oclacitinib was responsible for the 
adverse events. For concomitant medication, various antibiotics were used 
temporarily during oclacitinib administration and these combination therapies 
were well tolerated by most dogs. With regard to the parameters of clinical 
pathology, abnormal changes outside of the reference ranges were observed 
in some dogs. However, most of these were transient and unaccompanied by 
any correlated clinical signs. In one dog, ALP levels increased above the 
reference range during the study. However, the dog was found to have a 
high ALP level before oclacitinib treatment and no abnormal clinical signs 
were accompanied.
The present study was limited by several factors. First, the number of dogs 
receiving oclacitinib up to 84 days was small. For a better understanding of 
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the result of oclacitinib administration for more than 1 month, a further 
study with larger number of dogs might be needed. Second, the subjects 
were client-owned dogs. Because of the background, it was somewhat 
difficult to control all the factors that could affect TEWL values. Although 
we guided the owners on what to avoid during the trial, a few of them 
patted their dogs with a dry towel or had their dogs clipped on or near the 
day of assessment. Since towel drying and clipping are known to increase 
TEWL by causing damage to skin [16, 23], it is assumed that these 
behaviors diluted the possible positive effect of oclacitinib on skin barrier 
function.
In conclusion, the present study proved that oclacitinib improved skin 
barrier function by reducing the total TEWL value including some 
region-specific TEWL values significantly from baseline when administered 
twice daily. Even though TEWL tended to get worsen with the reduction of 
daily dosage by half, the change did not markedly aggravate the visible skin 
condition and the severity of pruritus compared to that at baseline as 
confirmed by the CADESI-4 and PVAS values. Lastly, most owners were 
satisfied with oclacitinib treatment throughout the study and the medication 
was used safely in most patients without causing any severe adverse effects. 
Therefore, oclacitinib was proven effective and safe for the control of canine 
allergic dermatitis throughout the study.
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Table 1. Baseline characteristics of enrolled dogs
Case Breed Age Sex Weight
1 Shih-tzu 14 Castrated Male 7.1
2 Shih-tzu 8 Castrated Male 5.8
3 Shih-tzu 9 Spayed Female 4.4
4 Maltese 8 Castrated Male 3.4
5 Dachshund 10 Castrated Male 7.2
6 Shih-tzu 10 Castrated Male 6.7
7 Poodle 2 Spayed Female 3.6
8 Golden Retriever 2 Female 32
9 French Bulldog 8 Spayed Female 9.6
10 Beagle 14 Castrated Male 17.6
11 Lakeland Terrier 1 Spayed Female 6.3
12 Poodle 4 Castrated Male 3.2
13 Bull terrier 7 Female 15.5
14 Maltese 6 Castrated Male 4.9
15 Bull dog 4 Spayed Female 17
16 Maltese 6 Castrated Male 5.1
17 Beagle 14 Castrate Male 17.6
18 Bichon Frise 5 Spayed Female 4.7
19 French Bulldog 2 Castrated Male 20.2
20 Poodle 2 Castrated Male 4
21 Pekingese 13 Castrated Male 5.9
22 Bichon Frise 5 Castrated Male 6.7
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Figure 1. Changes in canine atopic dermatitis extent and severity index-4 
values. (Day 0-14: n = 22, Day 56-84: n = 8) Results are expressed as 
mean value ± SD. * ; significant difference from baseline (p<0.05).
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Figure 2. Changes in pruritus visual analog scale values. 
(Day 0-14: n = 22, Day 56-84: n = 8). Results are expressed as mean 
value ± SD. * ; significant difference from baseline (p<0.05).
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Figure 3A. Changes in regional transepidermal water loss values. 
(Day 0-14: n = 22, Day 56-84: n = 8). * ; significant difference from 
baseline (p<0.05).
Figure 3B. Changes in total transepidermal water loss values. 
(Day 0-14: n = 22, Day 56-84: n = 8). Results are expressed as median 
value with IQR. * ; significant difference from baseline (p<0.05).
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Figure 4. Owner satisfaction. 
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Supplement 1. Consent form of the study
알러지 환자에 대한 Oclacitinib의
유효성 및 안전성 평가 임상시험 참가 동의서
환자명:                  나이:                  성별:               
품종:
보호자명:                연락처:
 Oclacitinib은 아토피를 포함한 다양한 알러지 증상을 나타내는 반려견 환
자들의 만성적인 가려움증을 비교적 빠르고 안전하게 완화시켜주는 약물
로써 현재 FDA의 승인을 받아 미국에서 현재 120만 마리의 개에게 사용 
되어 온 약품입니다. 본 임상시험은 환자 당 약 3개월간 진행(0주차, 2주
차, 4주차, 8주차, 12주차 내원)되며, 심한 통증을 유발할 수 있는 침습적
인 검사를 제외한 전신 피부증상 평가, 피부표면 수분 손실도, 가려움증 
평가 및 혈액검사(0주차, 4주차, 12주차)로 진행됩니다. 또한 임상시험 결
과에 대한 환자의 정보만 노출 되며 보호자에 대한 정보는 공개되지 않습
니다.
보호자__________________는 위 참가 동의서의 안내사항을 모두 이해했으
며, 알러지 환자에 대한 oclacitinib의 유효성 및 안전성 평가 연구를 위해 
_________________의 기본 신체검사 및 피부평가, 혈액검사, oclacitinib 복
용에 동의합니다.
2016.      .        .




알레르기성 피부염을 지닌 개에서 
Oclacitinib의 피부장벽 기능에 대한 평가




 소양감은 개 알레르기성 피부염을 진행시키는 주요 인자 중 하나이며, 몸
을 긁거나 핥는 행동들은 유발시킴으로써 피부장벽의 기능을 손상시킨다. 
피부장벽이 손상되면 외부에서 알레르기 유발성 물질들이 체내로 더욱 쉽
게 침투하게 되며 결과적으로 알레르기성 피부염의 중증도가 악화된다. 
Oclacitinib은 Janus kinase 1 (JAK-1) 억제제로서 소양감 발생에 관여하는 
사이토카인인 IL-31의 작용을 차단하는 주요 기전을 지닌 약제이며, 이러
한 기전을 통해 개 알레르기성 피부염을 완화시키는 약제로서 사용되고 
있다. 본 연구의 주요 목적은 경표피수분손실도(transepidermal water loss, 
TEWL)의 측정을 통해 개 알러지성 피부염에 대한 oclacitinib의 투여가 피
부장벽 기능에 미치는 영향을 평가하는 것이였으며, 이 밖에도 oclacitinib 
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치료의 효과와 안전성을 전반적으로 평가하였다. 본 연구에서는 총 22 마
리의 개에게 oclacitinib을 28 일간 투여하였으며, 그 중 8 마리는 보호자의 
동의를 받아 추가 투여를 진행하여 총 84 일간 약제를 투여하였다. 
Oclacitinib은 초기 2 주간 하루 2회 투여 되었으며, 그 이후로는 유지요법
으로서 하루 1회 투여되었다. Oclacitinib의 유효성 평가를 위해 TEWL 수
치 뿐만 아니라, 아토피성 피부염의 범위 및 중증도를 평가하는 canine 
atopic dermatitis extent and severity index-4 (CADESI-4), 소양감의 정도를 
평가하는 pruritus visual analog scale (PVAS) 및 보호자 만족도를 투여 전, 
투여 후 14, 28, 56 및 84일에 평가하였다. 또한 oclacitinib의 안전성 평가
를 위해 시험기간 동안 발생하는 부작용을 모두 기록하고, 투여 전, 투여 
후 28 및 84일에 혈액 시료를 채취하였다. Oclacitinib의 투여 결과, 
CADESI-4 및 PVAS 수치가 모든 평가 시점에서 약제의 투여 횟수에 관계
없이, 기저치 대비 유의하게 감소되었다(p<0.05). 앞선 결과와 달리 TEWL 
수치의 경우, 기저치 대비 유의한 감소가 투여 후 14일에서만 나타났으며, 
이러한 변화는 총 TEWL, 배측 목 부위 및 겨드랑이 부위의 TEWL 수치
에서 확인되었다(p<0.05). 시험기간 동안 대부분의 보호자들은 oclacitinib 
치료에 만족한다고 응답하였으며, 심각한 부작용은 관찰되지 않았다. 결론
적으로 oclacitinib은 하루 2회 투여되었을 때 피부장벽 기능 개선에 유의한 
효과를 나타낸다는 점을 확인할 수 있었다. 비록 일일 투여 횟수가 하루 1
회로 감소함에 따라 피부장벽 기능이 다시 악화되는 경향을 보였지만, 이
는 육안적 병변이나 소양감의 정도를 변화시킬 만큼 두드러진 영향을 미
치지 않았다. Oclacitinib 치료 효과에 대해 대부분의 보호자들은 긍정적인 
평가를 내렸으며, 대부분의 개에게 심각한 부작용을 유발하지 않으며 안전
하게 사용되었다. 따라서 본 연구는 oclacitinib이 개 알레르기성 피부염을 
조절하는데 있어 효과적이고 안전한 약제임을 확인하였다. 
__________________________________________________________________
주요단어: 알레르기성 피부염, oclacitinib, 피부장벽 기능, 소양감, 개 
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